Abstract
Objectives To measure the impact of beliefs, expectations, side effects, and their combined effects on the risk for medication non-persistence.
Design A population-based questionnaire.
Setting and Participants Individuals from Saskatchewan, Canada who started a new antihypertensive, cholesterol-lowering, or antihyperglycemic medication were surveyed about risk factors for non-persistence including: (a) beliefs measured by a composite score of three questions asking about the threat of the condition, importance of the drug, and harm of the drug; (b) incident side effects attributed to treatment; and (c) expectations for side effects before starting treatment. Descriptive statistics and logistic regression models were used to quantify the influence of these risk factors on the outcome of non-persistence. Odds ratios (OR) and 95% confidence intervals (CI) were estimated.
Main Outcome Measure Self-reported medication non-persistence.
Results Among 3,029 respondents, 5.9% (n=179) reported non-persistence within four months after starting the new drug. After adjustment for numerous covariates representing socio-demographics, healthcare providers, medication experiences and beliefs, both negative beliefs (OR 7.26, 95% CI: 4.98 to 10.59) and incident side effects (OR 8.00, 95% CI 5.49 to 11.68) were associated with the highest odds of non-persistence with no evidence of interaction. In contrast, expectations for side effects before starting treatment exhibited an important interaction with incident side effects following treatment initiation. Among respondents with incident side effects (n=741, 24.5%), the risk for early non-persistence was 11.5% if they indicated an expectation for side effects before starting the medication compared to 23.6% if they did not (adjusted OR 0.38, 95% CI 0.25 to 0.60).
Conclusions Expectations for side effects may be a previously unrecognized but important marker of the probability to persist with treatment. A high percentage of new medication users appeared unprepared for the possibility of side effects from their new medication making them less resilient if side effects occur.
What is already known on this topic
Prior expectations for side effects are thought to increase the risk for nocebo effects and increase the risk for medication non-persistence.
Medication non-persistence remains a major threat to patient outcomes.
What this study adds
Expectations for side effects from medications may be a previously unrecognized protective factor against non-persistence.
A high percentage of new medication users appear unprepared for the possibility of side effects from their new medication making them less resilient if side effects occur.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Blackburn, Taylor, Eurich, Lix, and Choudhry received grant funding from the Canadian Institutes of Health Research (CIHR grant number 130343) for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study was approved by the University of Saskatchewan Committee for Ethics in Human Research.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.